ClariTrial | Search Clinical Trials

Explore/eye disease ophthalmology retina

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

156 results for “eye disease ophthalmology retina” · Recruiting

Page 1 of 11

Recruiting

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Phase 3Neovascular Age-Related Macular Degeneration (nAMD)

4D-150 IVT (3E10 vg/eye)EYLEA® (aflibercept) Injection 2 mg (0.05mL)

4D Molecular Therapeutics480 participants94 sites · United States, Argentina, AustraliaCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

Phase 2Macular Edema

BI 1815368Placebo

Boehringer Ingelheim300 participants97 sites · United States, China, CzechiaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Advancing Pediatric Retinal Imaging With Auto-aligned OCT

N/AEye DiseasesRetinal DiseaseGlaucoma

Auto-aligned OCT

Duke University50 participants1 site · United StatesCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

Phase 2Moderate to Severe Vernal Keratoconjunctivitis

Slit Lamp ExaminationFar Best Corrected Visual Acuity (BCVA)T1695+2 more

Laboratoires Thea120 participants11 sites · IndiaCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Arterial Spin Labeling MRI for Assessing Blood Perfusion in the Human Eye Repeatability Study and Clinical Application

N/ARetinal Diseases

MRI perfusion imaging using ASL's non-invasive technique

Cliniques universitaires Saint-Luc- Université Catholique de Louvain70 participants1 site · BelgiumCompletes Jun 2026

Compare CT.gov Full analysis →

Recruiting

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Phase 2Geographic Atrophy (GA)Age - Related Macular Degeneration (AMD)

ONL1204 Opthalmic solutionAvacincaptad Pegol intravitreal solutionSham

ONL Therapeutics324 participants120 sites · United States, Austria, CanadaCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Optimization and Evaluation of the Diagnosis and Treatment System for Diabetic Retinopathy in Type 2 Diabetes Mellitus

N/ADiabetesDiabetic RetinopathyType 2 Diabetes Mellitus (T2DM)

Fundus ExaminationMetabolomics analysis

Yufan Wang2,920 participants3 sites · ChinaCompletes Aug 2025

Compare CT.gov Full analysis →

Recruiting

Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM

N/AEpiretinal Membrane

Immediate VitrectomyDeferred Vitrectomy

Jaeb Center for Health Research400 participants48 sites · United States, United KingdomCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Phase 3Neovascular Age-related Macular DegenerationnAMD

ABP 938 8 mgAflibercept (US) 8 mg

Amgen304 participants58 sites · United States, Latvia, PolandCompletes Jul 2027

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

N/ARetinopathy of Prematurity (ROP)

Conbercept

Wang Yusheng146 participants3 sites · ChinaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects

N/AGlaucoma, Open-AngleNormal Tension GlaucomaOcular Hypertension

Fourier Domain Doppler Optical Coherence Tomography (FDOCT)Dynamic Vessel Analyzer (DVA)Pattern Electroretinography (pERG)+2 more

Medical University of Vienna120 participants1 site · AustriaCompletes Mar 2026

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD

N/AIntermediate AMD

reSEES

Oculox Technologies SA30 participants1 site · ItalyCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2

N/AEye DiseasesVisual ImpairmentGlaucoma

Standard optometric examinationTechnology enhanced eye disease detection protocol

University of Michigan900 participants1 site · United StatesCompletes Aug 2030

Compare CT.gov Full analysis →

Recruiting

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

Phase 1Phase 2Retinitis Pigmentosa (RP)Age Related Macular DegenerationDiabetic Retinopathy

ACE Retino

Ace Cells Lab Limited100 participants2 sites · EgyptCompletes Jun 2025

Compare CT.gov Full analysis →

Recruiting

N/AAge-Related Macular Degeneration

Retinal Imaging

University of Wisconsin, Madison1,000 participants14 sites · United States, Argentina, AustraliaCompletes Nov 2026

Compare CT.gov Full analysis →

1–15 of 156

Explore/eye disease ophthalmology retina

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

156 results for “eye disease ophthalmology retina” · Recruiting

Page 1 of 11

Recruiting

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Phase 3Neovascular Age-Related Macular Degeneration (nAMD)

4D-150 IVT (3E10 vg/eye)EYLEA® (aflibercept) Injection 2 mg (0.05mL)

4D Molecular Therapeutics480 participants94 sites · United States, Argentina, AustraliaCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

Phase 2Macular Edema

BI 1815368Placebo

Boehringer Ingelheim300 participants97 sites · United States, China, CzechiaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Advancing Pediatric Retinal Imaging With Auto-aligned OCT

N/AEye DiseasesRetinal DiseaseGlaucoma

Auto-aligned OCT

Duke University50 participants1 site · United StatesCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

Phase 2Moderate to Severe Vernal Keratoconjunctivitis

Slit Lamp ExaminationFar Best Corrected Visual Acuity (BCVA)T1695+2 more

Laboratoires Thea120 participants11 sites · IndiaCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Arterial Spin Labeling MRI for Assessing Blood Perfusion in the Human Eye Repeatability Study and Clinical Application

N/ARetinal Diseases

MRI perfusion imaging using ASL's non-invasive technique

Cliniques universitaires Saint-Luc- Université Catholique de Louvain70 participants1 site · BelgiumCompletes Jun 2026

Compare CT.gov Full analysis →

Recruiting

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Phase 2Geographic Atrophy (GA)Age - Related Macular Degeneration (AMD)

ONL1204 Opthalmic solutionAvacincaptad Pegol intravitreal solutionSham

ONL Therapeutics324 participants120 sites · United States, Austria, CanadaCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Optimization and Evaluation of the Diagnosis and Treatment System for Diabetic Retinopathy in Type 2 Diabetes Mellitus

N/ADiabetesDiabetic RetinopathyType 2 Diabetes Mellitus (T2DM)

Fundus ExaminationMetabolomics analysis

Yufan Wang2,920 participants3 sites · ChinaCompletes Aug 2025

Compare CT.gov Full analysis →

Recruiting

Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM

N/AEpiretinal Membrane

Immediate VitrectomyDeferred Vitrectomy

Jaeb Center for Health Research400 participants48 sites · United States, United KingdomCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Phase 3Neovascular Age-related Macular DegenerationnAMD

ABP 938 8 mgAflibercept (US) 8 mg

Amgen304 participants58 sites · United States, Latvia, PolandCompletes Jul 2027

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

N/ARetinopathy of Prematurity (ROP)

Conbercept

Wang Yusheng146 participants3 sites · ChinaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects

N/AGlaucoma, Open-AngleNormal Tension GlaucomaOcular Hypertension

Fourier Domain Doppler Optical Coherence Tomography (FDOCT)Dynamic Vessel Analyzer (DVA)Pattern Electroretinography (pERG)+2 more

Medical University of Vienna120 participants1 site · AustriaCompletes Mar 2026

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD

N/AIntermediate AMD

reSEES

Oculox Technologies SA30 participants1 site · ItalyCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2

N/AEye DiseasesVisual ImpairmentGlaucoma

Standard optometric examinationTechnology enhanced eye disease detection protocol

University of Michigan900 participants1 site · United StatesCompletes Aug 2030

Compare CT.gov Full analysis →

Recruiting

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

Phase 1Phase 2Retinitis Pigmentosa (RP)Age Related Macular DegenerationDiabetic Retinopathy

ACE Retino

Ace Cells Lab Limited100 participants2 sites · EgyptCompletes Jun 2025

Compare CT.gov Full analysis →

Recruiting

N/AAge-Related Macular Degeneration

Retinal Imaging

University of Wisconsin, Madison1,000 participants14 sites · United States, Argentina, AustraliaCompletes Nov 2026

Compare CT.gov Full analysis →

1–15 of 156